Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids

Nature Medicine

Volumn 21, Issue 11, 2015, Pages 1364-1371

  Huang, Ling ^a   Holtzinger, Audrey ^a,b   Jagan, Ishaan ^a   Begora, Michael ^a   Lohse, Ines ^a   Ngai, Nicholas ^a   Nostro, Cristina ^a,b   Wang, Rennian ^c   Muthuswamy, Lakshmi B ^a   Crawford, Howard C ^d   Arrowsmith, Cheryl ^a,e   Kalloger, Steve E ^f,g,h   Renouf, Daniel J ^g,h,i   Connor, Ashton A ^j   Cleary, Sean ^j   Schaeffer, David F ^f,g,h   Roehrl, Michael ^a   Tsao, Ming Sound ^a,b   Gallinger, Steven ^j   Keller, Gordon ^a,b   Muthuswamy, Senthil K ^a   more..

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e Structural Genomics Consortium   (Canada)

^f VANCOUVER GENERAL HOSPITAL   (Canada)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h Centre for Disease Control   (Canada)

ⁱ BRITISH COLUMBIA CANCER AGENCY   (Canada)

^j UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; ASCORBIC ACID; CASPASE 3; COLLAGEN TYPE 4; CYTOKERATIN 19; FIBROBLAST GROWTH FACTOR 2; GEMCITABINE; GLUCOSE TRANSPORTER 1; HYDROCORTISONE; INSULIN; K RAS PROTEIN; MUCIN 1; PROTEIN; PROTEIN P53; PROTEIN ZO1; PTF1A PROTEIN; TRANSCRIPTION FACTOR CDX2; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR GATA 6; TRANSCRIPTION FACTOR NKX2.2; TRANSCRIPTION FACTOR NKX6.1; TRANSCRIPTION FACTOR PDX 1; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR SOX9; UNC 1999; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN P21; RAS PROTEIN; SOX9 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL METABOLIC RATE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KARYOTYPING; MORTALITY; MOUSE; NONHUMAN; OVERALL SURVIVAL; OXYGEN CONSUMPTION; PANCREAS ADENOCARCINOMA; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STEM CELL CULTURE; TIME LAPSE IMAGING; TRANSMISSION ELECTRON MICROSCOPY; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; BIOLOGICAL MODEL; CARCINOMA, PANCREATIC DUCTAL; CYTOPLASM; DRUG EFFECTS; DRUG SCREENING; GENETICS; METABOLISM; MUTATION; PANCREAS; PANCREATIC NEOPLASMS; PATHOLOGY; PROCEDURES; TISSUE CULTURE TECHNIQUE; ULTRASTRUCTURE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, PANCREATIC DUCTAL; DEOXYCYTIDINE; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MICE; MODELS, BIOLOGICAL; MUTATION; ORGANOIDS; PANCREAS; PANCREATIC NEOPLASMS; PLURIPOTENT STEM CELLS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS P21(RAS); RAS PROTEINS; SOX9 TRANSCRIPTION FACTOR; TISSUE CULTURE TECHNIQUES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84946215806     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3973     Document Type: Article

References (32)

1. Ghaneh, P., Costello, E. & Neoptolemos, J. P. Biology and management of pancreatic cancer. Postgrad. Med. J. 84, 478-497 (2008).
2. Kanji, Z. S. & Gallinger, S. Diagnosis and management of pancreatic cancer. CMAJ 185, 1219-1226 (2013).
3. Vincent, A., Herman, J., Schulick, R., Hruban, R. H. & Goggins, M. Pancreatic cancer. Lancet 378, 607-620 (2011).
4. Agbunag, C., Lee, K. E., Buontempo, S. & Bar-Sagi, D. Pancreatic duct epithelial cell isolation and cultivation in two-dimensional and three-dimensional culture systems. Methods Enzymol. 407, 703-710 (2006).
5. Huch, M. et al. Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5/R-spondin axis. EMBO J. 32, 2708-2721 (2013).
6. Li, X. et al. Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture. Nat. Med. 20, 769-777 (2014).
7. Pagliuca, F. W. et al. Generation of functional human pancreatic beta cells in vitro. Cell 159, 428-439 (2014).
8. Rezania, A. et al. Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat. Biotechnol. 32, 1121-1133 (2014).
9. Schiesser, J. V. & Wells, J. M. Generation of beta cells from human pluripotent stem cells: are we there yet? Ann. NY Acad. Sci. 1311, 124-137 (2014).
10. Jennings, R. E. et al. Development of the human pancreas from foregut to endocrine commitment. Diabetes 62, 3514-3522 (2013).
11. Pan, F. C. & Wright, C. Pancreas organogenesis: from bud to plexus to gland. Dev. Dyn. 240, 530-565 (2011).
12. McCracken, K. W. & Wells, J. M. Molecular pathways controlling pancreas induction. Semin. Cell Dev. Biol. 23, 656-662 (2012).
13. Hick, A. C. et al. Mechanism of primitive duct formation in the pancreas and submandibular glands: a role for SDF-1. BMC Dev. Biol. 9, 66 (2009).
14. Riedel, M. J. et al. Immunohistochemical characterisation of cells co-producing insulin and glucagon in the developing human pancreas. Diabetologia 55, 372-381 (2012).
15. Lyttle, B. M. et al. Transcription factor expression in the developing human fetal endocrine pancreas. Diabetologia 51, 1169-1180 (2008).
16. Outzen, H. C. & Leiter, E. H. Transplantation of pancreatic islets into cleared mammary fat pads. Transplantation 32, 101-105 (1981).
17. Laitio, M., Lev, R. & Orlic, D. The developing human fetal pancreas: an ultrastructural and histochemical study with special reference to exocrine cells. J. Anat. 117, 619-634 (1974).
18. Nielsen, S. K. et al. Characterization of primary cilia and Hedgehog signaling during development of the human pancreas and in human pancreatic duct cancer cell lines. Dev. Dyn. 237, 2039-2052 (2008).
19. Kolodecik, T., Shugrue, C., Ashat, M. & Thrower, E. C. Risk factors for pancreatic cancer: underlying mechanisms and potential targets. Front. Physiol. 4, 415 (2013).
20. Chang, D. K., Grimmond, S. M. & Biankin, A. V. Pancreatic cancer genomics. Curr. Opin. Genet. Dev. 24, 74-81 (2014).
21. Chakravarty, G., Rider, B. & Mondal, D. Cytoplasmic compartmentalization of SOX9 abrogates the growth arrest response of breast cancer cells that can be rescued by trichostatin A treatment. Cancer Biol. Ther. 11, 71-83 (2011).
22. Chakravarty, G. et al. Prognostic significance of cytoplasmic SOX9 in invasive ductal carcinoma and metastatic breast cancer. Exp. Biol. Med. (Maywood) 236, 145-155 (2011).
23. Marusyk, A., Almendro, V. & Polyak, K. Intra-tumour heterogeneity: a looking glass for cancer? Nat. Rev. Cancer 12, 323-334 (2012).
24. Waddell, N. et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518, 495-501 (2015).
25. van den Beucken, T. et al. Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. Nat. Commun. 5, 5203 (2014).
26. Johnson, A. B., Denko, N. & Barton, M. C. Hypoxia induces a novel signature of chromatin modifications and global repression of transcription. Mutat. Res. 640, 174-179 (2008).
27. Viale, A. et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 514, 628-632 (2014).
28. Boj, S. F. et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 160, 324-338 (2015).
29. Nostro, M. C. et al. Stage-specific signaling through TGF-family members and WNT regulates patterning and pancreatic specification of human pluripotent stem cells. Development 138, 861-871 (2011).
30. Nostro, M. C. et al. Efficient generation of NKX6-1+ pancreatic progenitors from multiple human pluripotent stem cell lines. Stem Cell Reports 4, 591-604 (2015).
31. Xiang, B. & Muthuswamy, S. K. Using three-dimensional acinar structures for molecular and cell biological assays. Methods Enzymol. 406, 692-701 (2006).
32. Ritchie, M. E. et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).